-
Refugees resettling to the United States and other developed countries frequently suffer from infectious diseases, and can pose diagnostic or therapeutic dilemmas for health care providers in their new homes.
-
This multicenter, randomized, placebo-controlled trial of a synthetic GHRH analogue, tesamorelin (1-44 amino acids from the amino terminal of GHRH with a trans-3-hexenoyl group added to the amino terminal to increase the half-life over native GHRH), randomized 412 patients (86% male) to daily subcutaneous tesamorelin vs placebo for 26 weeks.
-
Sixty-one hospitals in 28 countries participated in a prospective cohort study of hospitalized patients with definite endocarditis.
-
The diagnosis of malaria has traditionally relied upon microscopy. However, microscopic diagnosis is labor intensive and somewhat subjective, and assurance of quality standards can be difficult at best.
-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
At the 56th annual meeting of the American Society of Tropical Medicine and Hygiene held Nov. 4-8, 2007, in Philadelphia, Paul Arguin, MD, Chief of the Domestic Malaria Unit at the Centers for Disease Control and Prevention, presented the Malaria Prevention Update from the CDC.
-
A clinical pre-meeting course at the 56th annual meeting at ASTMH was conducted and entitled, Chagas' Disease: (American Trypanosomiasis): No Longer an Exotic Disease.
-
-
A symposium on Plasmodium Vivax (P. vivax) malaria was held at the recent annual meeting of the American Society of Tropical Medicine and Hygiene in Philadelphia.
-
The incidence of chicken pox has decreased dramatically in the United States since implementation of a universal vaccination program in 1995. However, the question of whether or not there is waning immunity to varicella after one dose of vaccine led Chaves and colleagues to investigate the incidence of varicella in individuals vaccinated with one dose of varicella zoster virus (VZV) vaccine between 1995 and 2004.
